MigraineMind research summary
Effectiveness of Onabotulinumtoxin-A in Patients with Chronic Migraine and Previous CGRP-mAb Treatment Failure: A Multicentre 6-Month Real-World Experience.
Toxins (Basel) | 2026
Observational studySummary
Many patients with chronic migraine (CM) do not respond to standard treatments. Sometimes, they fail to benefit from medications targeting the CGRP pathway. This study looked at onabotulinumtoxin-A (BoNT-A) for these patients. Researchers enrolled patients who had tried at least three oral treatments and one CGRP medication. These patients received BoNT-A injections every three months for six months. The study measured changes in monthly headache days (MHD) and the percentage of patients who reduced their MHD by 50% or more. Results showed that BoNT-A was effective for many patients who had previously struggled with other treatments. The findings suggest that BoNT-A could be a valuable option for patients with chronic migraine who have not found relief from other therapies. Overall, this study adds important information about treating chronic migraine in difficult cases. Clinical relevance: This research indicates that onabotulinumtoxin-A may effectively help chronic migraine patients who previously failed CGRP treatments.
Key Learning Points
- Many patients with chronic migraine do not find relief from standard treatments, including those targeting the CGRP pathway.
- Onabotulinumtoxin-A injections every three months may help patients who have not responded to other migraine therapies.
- The study showed that BoNT-A was effective in reducing monthly headache days for many patients with chronic migraine.
- A significant percentage of patients experienced at least a 50% reduction in their headache days after receiving BoNT-A.
- This research highlights the potential of BoNT-A as a valuable treatment option for chronic migraine patients with limited success from other medications.
Research Informatics
REAL-WORLD STUDY
BoNT-A may help chronic migraine after CGRP-mAb failure.
conditionChronic migraine
sample Size53
populationCM patients with prior CGRP-mAb and oral preventive failures
study DesignProspective cohort
exposureOnabotulinumtoxin-A treatment
study Period6 months
Related migraine research topics
Original research
Read the original publication and review its full methods and findings on PubMed.
MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.